Gemfibrozil stimulates apolipoprotein A-I synthesis and secretion by stabilization of mRNA transcripts in human hepatoblastoma cell line (Hep G2)

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 16, Issue 8, 1996, Pages 1052-1062

  Jin, Fu You ^b   Kamanna, Vaijinath S ^b   Chuang, Mei Yu ^b   Morgan, Kengathevy ^b   Kashyap, Moti L ^a  

^a VA LONG BEACH HEALTHCARE SYSTEM   (United States)

^b NONE

Author keywords

apolipoprotein A I gene expression; atherosclerosis; cellular cholesterol efflux; coronary artery disease; reverse cholesterol transport

Indexed keywords

APOLIPOPROTEIN A1; CHOLESTEROL; GEMFIBROZIL;

ARTICLE; ATHEROSCLEROSIS; CHOLESTEROL TRANSPORT; CORONARY ARTERY DISEASE; GENE EXPRESSION; HEPATOBLASTOMA; HUMAN; HUMAN CELL; LIPOPROTEIN METABOLISM; LIPOPROTEIN SECRETION; LIPOPROTEIN SYNTHESIS; PRIORITY JOURNAL; RNA TRANSCRIPTION; RNA TRANSLATION;

EID: 0029793860     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.16.8.1052     Document Type: Article

References (58)

1. Kashyap ML. Basic considerations in the reversal of atherosclerosis: significance of high density lipoproteins in stimulating reverse cholesterol transport. Am J Cardiol. 1989;63:56H-59H.
2. Fielding CJ, Fielding PE. Cholesterol transport between cells and body fluids. Med Clin North Am. 1982;66:363-373.
3. Maciejko JJ, Holmes DR, Kottke BA. Apolipoprotein A-I is a marker of angiographically assessed coronary-artery disease. N Engl J Med. 1983;309:385-389.
4. Mendoza SG, Zerpa A, Carrasco H, Colmenares O, Rangel A, Gartside PS, Kashyap ML. Estradiol, testosterone, apolipoproteins, lipoprotein cholesterol, and lipolytic enzymes in men with premature myocardial infarction and angiographically assessed coronary occlusion. Artery. 1983;12:1-23.
5. Rubin EM, Krauss RM, Spangler EA, Verstuyft JG, Clift SM. Inhibition of early atherogenesis in transgenic mice by human apolipoprotein A-I. Nature. 1991;353:265-267.
6. Henrikson T, Evenson SA, Carlander B. Injury to cultured endothelial cells induced by LDL: protection of high density lipoproteins. Scand J Clin Lab Invest. 1979;3:369-375.
7. Saku K, Ahmad M, Glas-Greenwalt P, Kashyap ML. Activation of fibrinolysis by apolipoproteins of high density lipoproteins in man. Thromb Res. 1985;39:1-8.
8. Yoi Y. Serum prostacyclin stabilizing factor is identical to apolipoprotein A-I (apoA-I). J Clin Invest. 1988;82:803-807.
9. Plump AS, Scott CJ, Breslow JL. Human apolipoprotein A-I gene expression increases high density lipoprotein and suppresses atherosclerosis in the apolipoprotein E-deficient mouse. Proc Natl Acad Sci U S A. 1994;91:9607-9611.
10. Klatsky AL, Armstrong AM, Griedman GD. Alcohol and mortality. Ann Intern Med. 1992;117:646-654.
11. Canner PL, Berge KG, Wanger NK. Fifteen-year mortality in coronary drug project patients: long-term benefit with niacin. J Am Coll Cardiol. 1986;8:1245-1255.
12. Frick MH, Elo O, Kaapa K, Heinonen OP, Heinsalmi P, Helo P, Huttunen JK, Kaitaniemi P, Koskinen P, Manninen V, Malkonen M, Manttari M, Norola S, Pasternack A, Pikkarainen J, Romo M, Sjoblom T, Nikkila EA. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia: safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med. 1987;317:1237-1245.
13. Brown G, Albers JJ, Fisher LF. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N Engl J Med. 1990;323:1289-1298.
14. Stampfer MJ, Colditz GA. Estrogen replacement therapy and coronary heart disease: a quantitative assessment of the epidemiologic evidence. Prev Med. 1991;20:47-63.
15. Tarn S-P, Archer TK, Deeley RG. Effects of estrogen on apolipoprotein secretion by the human hepatocarcinoma cell line, HepG2. J Biol Chem. 1985;260:1670-1675.
16. Kashyap ML. Effects of drugs on high density lipoprotein apoprotein metabolism. In: Miller NE, ed. High Density Lipoproteins, Reverse Cholesterol Transport, and Coronary Heart Disease. Selected proceedings. Princeton, NJ: Excerpta Medica (Elsevier) Publishing Co;1989:60-68.
17. Bloomfield-Rubins H, Robins SJ, Iwane MK, Boden WE, Fye CL, Gordon DJ, Schaefer EJ, Schechtman G, Wittes JT, for the Department of Veterans Affairs HIT Study Group. Rationale and design of the Department of Veterans Affairs high-density lipoprotein cholesterol intervention trial (HIT) for secondary prevention of coronary artery disease in men with low high-density lipoprotein cholesterol and desirable low-density lipoprotein cholesterol. Am J Cardiol. 1993;71:45-52.
18. Bloomfield-Rubins H, Robins SJ, Collins D, Iranmanesh A, Wilt TJ, Mann D, Mayo-Smith M, Pass FH, Elam MB, Rutan GH, Anderson JW, Kashyap M, Schechtman G. Distribution of lipids in 8500 men with coronary artery disease. Am J Cardiol. 1995;75:1196-1201.
19. The Bezafibrate Infarction Prevention (BIP) Study Group Israel. Lipids and lipoproteins in symptomatic coronary heart disease: distribution, intercorrelations, and significance for risk classification in 6700 men and 1500 women. Circulation. 1992;86:839-848.
20. Saku K, Gartside PS, Hynd BA, Kashyap ML. Mechanism of action of gemfibrozil on lipoprotein metabolism. J Clin Invest. 1985;75:1702-1712.
21. Zannis VI, Breslow JL, San Giacomo TR, Aden DP, Knowles BB. Characterization of the major apolipoproteins secreted by two human hepatomacell lines. Biochemistry. 1981;20:2089-2096.
22. Thrift R, Forte TM, Cahoon BE, Shore VG. Characterization of lipoproteins produced by the human liver cell line, Hep G2, under defined conditions. J Lipid Res. 1986;27:236-250.
23. Forte TM, McCall MR, Knowles BB, Shore VG. Isolation and characterization of lipoproteins produced by human hepatoma-derived cell lines other than HepG2. J Lipid Res. 1989;30:817-829.
24. Havel RJ, Eder HA, Bragdon JH. The distribution and characterization of ultracentrifugally separated lipoproteins in human serum. J Clin Invest. 1955;34:1345-1353.
25. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the Folin phenol reagent. J Biol Chem. 1951;193:265-275.
26. Maniatis T, Fritsch EF, Sambrook T. Analysis and cloning of eukaryotic genomic DNA. In: Nolan C, ed. Molecular Cloning: A Laboratory Manual. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory; 1989:14-23 ch 2, section 9.
27. Rothwell TC, Kamanna VS, Jin FY, Koren E, Foley T, Kashyap ML. Characterization of a monoclonal antibody (HB-22) and development of an enzyme-linked immunosorbent assay for human apolipoprotein A-I. Clin Chem. 1995;41:1150-1158.
28. Malmendier CL, Lontie JF, Lagrost L, Delcroix C, Dubois DY, Gambert P. In vivo metabolism of apolipoproteins A-IV and A-I associated with high density Hpoprotein in nurmolipidemic subjects. J Lipid Res. 1991;32:801-808.
29. McFarlane AS. Efficient trace-labeling of proteins with iodine. Nature. 1958;182:53.
30. Shepherd J, Gotto AM, Taunton OD, Claslake MJ, Parish E. The in vitro interaction of human apolipoprotein A-I and high density lipoproteins. Biochim Biophys Acta. 1977;489:486-501.
31. Gupta AK, Ross EA, Meyers JN, Kashyap ML. Increased reverse cholesterol transport in athletes. Metabolism. 1993;42:684-690.
32. Selam JL, Kashyap ML, Gupta AK, Turner D, Wong ND, Lozan JL, Charles MA. Alterations in reverse cholesterol transport associated with programmable implantable intraperitoneal insulin delivery. Metabolism. 1994;43:655-669.
33. Fielding CJ, Fielding PE. Evidence for a lipoprotein carrier in human plasma catalyzing sterol efflux from cultured fibroblasts and its relationship to lecithin:cholesterol acyltransferase. Proc Natl Acad Sci U S A. 1981;78:3911-3914.
34. Rothblatt GH, Bamberger MM, Phillips MC. Reverse cholesterol transport. In: Colowich SP, Kaplan NO, eds. Methods in Enzymology. Orlando, Fla: Academic Press; 1986;128:628-644.
35. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem. 1987;162:156-159.
36. Brown T. Analysis of RNA by Northern and slot blot hybridization. In: Ausubel FM, Brent R, Kingston RE, Moore DD, Seidman JG, Smith JA, Struhl K, eds. Current Protocols in Molecular Biology. Brooklyn, NY: John Wiley & Sons; 1993:1-14 ch 4, section 9.
37. Breslow JL, Ross D, McPherson J, Williams H, Kurnit D, Nussbaum AL, Karathanasis SK, Zannis VI. Isolation and characterization of cDNA clones for human apolipoprotein A-I. Proc Natl Acad Sci U S A. 1982;79:6861-6865.
38. Schaap AP, Akhavan H, Romanol J. Chemiluminescent substrates for alkaline phosphatase: application to ultrasensitive enzyme-linked immunoassays and DNA probes. Clin Chem. 1989;35:1863-1864.
39. Hu RM, Chuang MY, Prins B, Kashyap ML, Frank HJL, Pedram A, Levin ER. High density lipoproteins stimulate the production and secretion of endothelin-1 from cultured bovine aortic endothelial cells. J Clin Invest. 1994;93:1056-1062.
40. Hu RM, Levin ER, Pedram A, Frank HJL. Atrial natriuretic peptide inhibits the production and secretion of endothelin from cultured endothelial cells. J Biol Chem. 1992;267:17384-17389.
41. Greenberg ME. Identification of newly transcribed RNA. In: Ausubel FM, Brent R, Kingston RE, Moore DD, Seidman JG, Smith JA, Struhl K, eds. Current Protocols in Molecular Biology. Brooklyn, NY: John Wiley & Sons; 1993:1-11, ch 4, section 10.
42. Greenberg ME, Ziff EB. Stimulation of 3T3 cells induces transcription of the c-fos proto-oncogene. Nature. 1984;311:433-438.
43. Dashti N, Wolfbauer G, Alaupovic P. Binding and degradation of human high-density lipoproteins by human hepatoma cell line Hep G2. Biochim Biophys Acta. 1985;833:100-110.
44. Hahn SE, Goldberg DM. Modulation of lipoprotein production in Hep G2 cells by fenofibrate and clofibrate. Biochem Pharmacol. 1992;43:625-633.
45. Tam S. Effects of gemfibrozil and ketoconazole on human apolipoprotein A-I, B, and E levels in two hepatoma cell lines, Hep G2 and Hep 3B. Atherosclerosis. 1991;91:51-61.
46. Puchois P, Kandoussi A, Fievet P, Fourrier JL, Bertr M, Koren E, Fruchart JC. Apolipoprotein A-I-containing lipoproteins in coronary artery disease. Atherosclerosis. 1987;68:35-40.
47. Warden CH, Kedrick CC, Qiao JH, Castellani LW, Lusis AJ. Atherosclerosis in transgenic mice overexpressing apolipoprotein A-II. Science. 1993;261:469-472.
48. Barbaras R, Puchois P, Fruchart JC, Ailhaud G. Cholesterol efflux from cultured adipose cells is mediated by Lp A-I particles but not by Lp A-I:A-II particles. Biochem Biophys Res Commun, 1987;142:63-69.
49. Cheung MC, Lum KD, Brouillette CG, Bisgaier CL. Characterization of apoA-I-containing lipoprotein subpopulations secreted by Hep G2 cells. J Lipid Res. 1989;30:1429-1436.
50. Johnson WJ, Kilsdonk EPC, Tol AV, Phillips MC, Rothblatt GH. Cholesterol efflux from cells to immunopurified subfractions of human high density lipoprotein: LP-A-I and LP-A-I/A-II. J Lipid Res. 1991;32:1993-2000.
51. Vu-Dac N, Schoonjans K, Laine B, Fruchart JC, Auwerx J, Staels B, Negative regulation of the human apolipoprotein A-I promoter by fibrates can be attenuated by the interaction of the peroxisome proliferator-activated receptor with its response element. J Biol Chem. 1994;269:31012-31018.
52. Vu-Dac N, Schoonjans K, Kosykh V, Dallongeville J, Fruchart JC, Staels B, Auwerx J. Fibrates increase human apolipoprotein A-II expression through activation of the peroxisome proliferator-activated receptor. J Clin Invest. 1995;96:741-750.
53. Malmendier CL, Delcroix C. Effects of fenofibrate on high and low density lipoprotein metabolism in heterozygous familial hypercholesterolemia. Atherosclerosis. 1985;55:161-169.
54. Jin FY, Chuang MY, Kashyap ML. Very-low-density lipoproteins inhibit hepatocyte (Hep G2) production of apolipoprotein A-I. 66th Scientific Sessions of the American Heart Association, Atlanta, Ga, November 8-11, 1993. Abstract.
55. Kissebah AH, Alfarsi S, Adams PW, Seed M, Folkar J, Wynn V. Transport kinetics of plasma free fatty acid, very low density lipoprotein triglycerides and apoprotein in patients with endogenous hypertriglyceridemia: effect of 2.2-dimethyl, 5(2,5-xylyl-oxy) valeric acid therapy. Atherosclerosis. 1976;24:199-218.
56. Manttari M, Tenkanen L, Maenpaa H, Mannine V, Huttunen JK. High-density lipoprotein cholesterol elevation with gemfibrozil: effects of baseline level and modifying factors. Clin Pharmacol Ther. 1993;54:437-447.
57. Rea TJ, Bisgaier CL, DeMattos RB, Pape ME. Rabbit liver apolipoprotein A-I synthesis is under non-parenchymal cell paracrine control. J Lipid Res. 1994;35:1274-1282.
58. Havel RJ, Kane JP, Kashyap ML. Interchange of apolipoprotein s between chylomicrons and high-density lipoproteins during alimentary lipemia in man. J Clin Invest. 1973;52:32-38.